文献速递精神分裂症与精神病性障碍

致幻剂治疗精神分裂症的可能性与安全实施策略

Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.
PubMed 文献 · Mol Psychiatry · 2022-10-24

本文探讨致幻剂在治疗精神分裂症阴性症状及皮质萎缩方面的潜在作用,并讨论诱导或加重精神病的风险及缓解策略。文章提出非致幻衍生物、亚致幻剂量或微剂量、利用致幻蘑菇提取物的伴生效应以及阻断5-HT2A受体介导的致幻效应等策略,并强调临床前研究和精心设计的临床研究是前提。

要点

  • 致幻剂可能通过增强神经可塑性改善精神分裂症皮质萎缩和阴性症状。
  • 治疗精神分裂症患者时需警惕诱导或加重精神病性症状的风险。
  • 非致幻衍生物、微剂量及阻断5-HT2A受体等策略可能降低风险。

核心结论

  • 致幻剂可能对精神分裂症的皮质萎缩和阴性症状有治疗作用,但需通过多种策略降低致幻风险。

研究设计与样本

  • 本文为观点性文章,基于临床前研究和部分人类研究证据进行论述。

主要发现

  • 阴性症状对现有抗精神病药物反应差,是精神分裂症致残的主要原因。
  • 致幻剂在抑郁症、面对终末期癌症的个体、创伤后应激障碍和成瘾等疾病中显示出疗效。
  • 临床前研究和部分人类研究证据表明致幻剂可增强神经可塑性。

关键数值与推荐

  • 精神分裂症影响全球0.5-1.0%的人口。

临床怎么用

  • 临床研究需基于临床前和转化数据精心设计,并采用合适的动物模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Schizophrenia is a widespread psychiatric disorder that affects 0.5-1.0% of the world's population and induces significant, long-term disability that exacts high personal and societal cost. Negative symptoms, which respond poorly to available antipsychotic drugs, are the primary cause of this disability. Association of negative symptoms with cortical atrophy and cell loss is widely reported. Psychedelic drugs are undergoing a significant renaissance in psychiatric disorders with efficacy reported in several conditions including depression, in individuals facing terminal cancer, posttraumatic stress disorder, and addiction. There is considerable evidence from preclinical studies and some support from human studies that psychedelics enhance neuroplasticity. In this Perspective, we consider the possibility that psychedelic drugs could have a role in treating cortical atrophy and cell loss in schizophrenia, and ameliorating the negative symptoms associated with these pathological manifestations. The foremost concern in treating schizophrenia patients with psychedelic drugs is induction or exacerbation of psychosis. We consider several strategies that could be implemented to mitigate the danger of psychotogenic effects and allow treatment of schizophrenia patients with psychedelics to be implemented. These include use of non-hallucinogenic derivatives, which are currently the focus of intense study, implementation of sub-psychedelic or microdosing, harnessing of entourage effects in extracts of psychedelic mushrooms, and blocking 5-HT2A receptor-mediated hallucinogenic effects. Preclinical studies that employ appropriate animal models are a prerequisite and clinical studies will need to be carefully designed on the basis of preclinical and translational data. Careful research in this area could significantly impact the treatment of one of the most severe and socially debilitating psychiatric disorders and open an exciting new frontier in psychopharmacology.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wolf G, Singh S, Blakolmer K, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2022. PMID: 36280752. doi:10.1038/s41380-022-01832-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。